Media Pack
News

Current Edition

Volume 16 Issue 1
 
Regional News

Novartis, determined to dethrone Pfizer, will launch bold Kisqali-Ibrance head-to-head trial in breast cancer

Despite two life extension wins, Novartis still finds it tough to convince doctors to use its breast cancer drug Kisqali over Pfizer’s first-to-market Ibrance. Now, w...
22 September 2021 Regional News breast cancer | Ibrance
Continue Reading →
Regional News

Merck’s Keytruda scores first-in-class nod in early triple-negative breast cancer despite FDA’s prior reluctance

The FDA had reservations about Merck & Co.’s proposed use of Keytruda around surgery for patients with early triple-negative breast cancer. But less than three mo...
4 August 2021 Regional News breast cancer | clinical trial
Continue Reading →
news

Novartis’ breast cancer drug Kisqali succeeds in phase 3 study in premenopausal women

Novartis’ Kisqali (ribociclib) combination therapy has succeeded in a phase 3 study in premenopausal women with hormone-receptor positive, human epidermal growth fact...
15 November 2017 news breast cancer | hormone
Continue Reading →
news

New Swedish study results at SABCS show DiviTum ® blood test reduces waiting times for evaluating breast cancer treatment

Results from a study of 142 women with newly diagnosed metastatic breast cancer will be presented by researchers from Lund University at the world’s biggest breast c...
15 November 2017 news biomarker | biopsy
Continue Reading →
 
 

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2024, All Rights Reserved – Powered by Teksyte